secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001493152-23-000232
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix reports positive Phase 1 results for inhaled migraine drug PUR3100; Tmax 5 min, fewer GI side effects
--------------------------------------------------------------------------------

- PUR3100 was safe and well-tolerated; no emesis in any dose group; lower nausea incidence vs IV DHE.
- Peak plasma concentration (Cmax) reached targeted therapeutic range at all three doses; Tmax of 5 minutes.
- Phase 2 dose selection underway; FDA meeting requested in January 2023.
- Study enrolled 26 healthy subjects in double-dummy, double-blinded design comparing inhaled PUR3100 vs IV DHE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223000232/0001493152-23-000232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223000232/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-000232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer